Variability of genes encoding surface proteins used as vaccine antigens in meningococcal endemic and epidemic strain panels from Norway (Q42223921)

18 October 2017

title

Variability of genes encoding surface proteins used as vaccine antigens in meningococcal endemic and epidemic strain panels from Norway (English)

1 reference

18 October 2017

1 reference

9

Rino Rappuoli

1 reference

18 October 2017

8

Mariagrazia Pizza

1 reference

18 October 2017

2

Maurizio Comanducci

1 reference

18 October 2017

3

Stefania Bambini

1 reference

18 October 2017

10

Dominique A Caugant

1 reference

18 October 2017

4

Alessandro Muzzi

1 reference

18 October 2017

5

Sara Comandi

1 reference

18 October 2017

7

Lisa DeTora

1 reference

18 October 2017

6

Jan Oksnes

1 reference

18 October 2017

Johan Holst

1

1 reference

18 October 2017

language of work or name

English

0 references

publication date

12 March 2014

1 reference

18 October 2017

1 reference

18 October 2017

volume

32

1 reference

18 October 2017

issue

23

1 reference

18 October 2017

page(s)

2722-2731

1 reference

Epidemic meningitis, meningococcaemia, and Neisseria meningitidis

18 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Development of natural immunity to Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Global epidemiology of meningococcal disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Serogroup B meningococcal vaccines-an unfinished story

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Review of meningococcal group B vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

A surveillance network for meningococcal disease in Europe.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Population-based analysis of meningococcal disease mortality in the United States: 1990-2002.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

The Changing Epidemiology of Meningococcal Disease in the United States, 1992–1996

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

inferred from DOI database lookup

7 January 2021

based on heuristic

Quadrivalent meningococcal conjugate vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

A prospective study of the effectiveness of the New Zealand meningococcal B vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Reverse vaccinology, a genome-based approach to vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Vaccine potential of the Neisseria meningitidis 2086 lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

A universal vaccine for serogroup B meningococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

The use of vaccine antigen characterization, for example by MATS, to guide the introduction of meningococcus B vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Neisseria meningitidis Infections in Northern Norway: An Epidemic in 1974-1975 Due Mainly to Group B Organisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Characterization of Neisseria meningitidis isolates from recent outbreaks in Ethiopia and comparison with those recovered during the epidemic of 1988 to 1989.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Clustal W and Clustal X version 2.0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) Software Version 4.0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

MEGA: a biologist-centric software for evolutionary analysis of DNA and protein sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

NadA, a novel vaccine candidate of Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Factor H binding and function in sialylated pathogenic neisseriae is influenced by gonococcal, but not meningococcal, porin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Effect of Factor H-Binding Protein Sequence Variation on Factor H Binding and Survival ofNeisseria meningitidisin Human Blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Factor H and neisserial pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

The covalent-binding reaction of complement component C3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.02.068

10.1016/J.VACCINE.2014.02.068

7 January 2021

Identifiers

DOI

1 reference

18 October 2017

1 reference